News

Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?
Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Novo Nordisk Stock Drops Further on Bank of America Downgrade
U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...
Novo Nordisk Shares Plummet as Competition Weighs on Sales
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Stock Movers: Novo Nordisk, Palo Alto, Union Pacific
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...